Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Recruiting at84 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: ACADIA Pharmaceuticals Inc.
Stay on Your Current Meds
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy
Research Team
Eligibility Criteria
Inclusion Criteria
Adult patients, aged 18 years and above
A clinical diagnosis of major depressive disorder (MDD)
Citalopram
See 7 more
Treatment Details
Interventions
- Pimavanserin (Serotonin inverse agonist/antagonist)
- Placebo (Drug)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug - pimavanserinExperimental Treatment1 Intervention
Pimavanserin 34 mg tablets
Group II: PlaceboPlacebo Group1 Intervention
Placebo tablets
Find a Clinic Near You
Who Is Running the Clinical Trial?
ACADIA Pharmaceuticals Inc.
Lead Sponsor
Trials
49
Recruited
11,700+
Founded
1993
Headquarters
San Diego, USA
Known For
Neurological Disorders
Top Products
Nuplazid (pimavanserin), Daybue (trofinetide)